Open-label extension study results show fenfluramine improves seizure control in LGS patients, indicating long-term safety.
Background/Purpose: Lennox–Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy characterized by tonic seizures and other seizure types, intellectual impairment, and specific electroencephalogram findings. We describe the final long-term safety and effectiveness data from an open-label extension (OLE) study evaluating fenfluramine (FFA) in patients with LGS (NCT03355209).
No takes yet. Share an insight, caveat, or question.
Knupp et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: